Insight

Ankit Mangla: Our analysis of data from neoadjuvant IO trials in melanoma has been published in JAMA Oncology

Photo of Ankit Mangla taken from X/Twitter

Apr 2, 2024, 12:20

Ankit Mangla: Our analysis of data from neoadjuvant IO trials in melanoma has been published in JAMA Oncology

Ankit Mangla, Sarcoma and Cutaneous Oncology Specialist at the Seidman Cancer Center, shared a post by JAMA Oncology on X/Twitter, adding:

“Hot off the press. Our analysis of data from neoadjuvant IO trials in melanoma published in JAMA Oncology. The phenomenal John M. Kirkwood mentored our team to develop this paper. Ipi3-nivo1 or ipi1-nivo3 or anti-pd1- which one to give? We provide some answers in this paper.”

Quoting JAMA Oncology’s paper:

“A pooled analysis of six clinical trials shows that while the odds of a favorable pathologic and radiologic response are high, the risk of adverse events is high with dual checkpoint inhibitors in resectable high-risk melanoma compared to anti-PD1 alone.”

Source: Ankit Mangla/X and JAMA Oncology/X

analysis Ankit Mangla anti-pd1 cancer checkpoint inhibitors clinical trials IO trials ipi1-nivo3 Ipi3-nivo1 JAMA Oncology John M. Kirkwood Melanoma OncoDaily Oncology paper pathological response radiological response

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage